$24.67
-0.43(-1.70%)
Mkt Cap $5.0B
$13.31
$27.75
52-Week Range
At A Glance
1
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
2
Most recently: shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or a (2026-02-06).
$5.0B
Market Cap
—
Revenue
-$521M
Net Income
Employees362
Fundamentals
How The Business Makes Money
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001764013
ISINUS45258J1025
CUSIP45258J102
Phone917 580 3099
Address320 West 37th Street, New York City, NY, 10018, US
SEC EDGAR